TORCH-Plus-DZHK21


Study information
TORCH-Plus-DZHK21

Recruiting status

Recruiting ongoing

Recruitment start

08/2020

Patients

3365

4340

Clinical Trials Registration

NCT04265040

Category

Registry

DZHK Funding

EUR 3.169.463,16

Operative contact:
Main study centre - Farbod Sedaghat-Hamedani, MD
Torch.Register@med.uni-heidelberg.de

Johannes Trebing, MD
johannes.trebing@med.uni-heidelberg.de

Studienzentren/Kontakt (PDF)

TranslatiOnal Registry for CardiomyopatHies-Plus (TORCH-Plus-DZHK21)

The overarching aim of TORCH-Plus is to create a large-scale prospective data & biomaterial repository of patients with non-ischemic cardiomyopathies (CMP). The scientists want to study clinical outcomes, familial structures, phenotype-genotype associations, autoimmunity, and inflammatory mechanisms as well as gender-related aspects. By long-term follow-up and systematic evaluation of CMP-related mechanisms, TORCH-Plus aims to identify and validate novel risk stratification algorithms to improve the outcome of patients ultimately.

Publications

Translational Registry for Cardiomyopathies (Torch) – Rationale and First Results. Seyler, C. et al. ESC heart failure, (2017).

All publications of this trial can be found here

Principal Investigators

Prof. Dr. Benjamin Meder
Universitätsklinikum Heidelberg

Study recruitment is available in these cities

The map only displays recruitment locations within Germany.